Robert Havard1, Deborah M Stephens2. 1. Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, 1950 Circle of Hope, Salt Lake City, UT, 84112, USA. 2. Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, 1950 Circle of Hope, Salt Lake City, UT, 84112, USA. Deborah.Stephens@hci.utah.edu.
Abstract
PURPOSE OF REVIEW: This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS: The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1, JULIET, and TRANSCEND NHL-001 trials. Anti-CD19 CAR-T therapy is an exciting new therapy now approved and available to patients with relapsed/refractory diffuse large B cell lymphoma. Secondary to the increasing success and availability of these products, caregivers should expect to become familiar with the indications, toxicity, and limitations of these treatment options and when patients should be considered for referral.
PURPOSE OF REVIEW: This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS: The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1, JULIET, and TRANSCEND NHL-001 trials. Anti-CD19 CAR-T therapy is an exciting new therapy now approved and available to patients with relapsed/refractory diffuse large B cell lymphoma. Secondary to the increasing success and availability of these products, caregivers should expect to become familiar with the indications, toxicity, and limitations of these treatment options and when patients should be considered for referral.
Authors: James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg Journal: Blood Date: 2011-12-08 Impact factor: 22.113
Authors: James N Kochenderfer; Mark E Dudley; Sadik H Kassim; Robert P T Somerville; Robert O Carpenter; Maryalice Stetler-Stevenson; James C Yang; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; Mark Raffeld; Steven Feldman; Lily Lu; Yong F Li; Lien T Ngo; Andre Goy; Tatyana Feldman; David E Spaner; Michael L Wang; Clara C Chen; Sarah M Kranick; Avindra Nath; Debbie-Ann N Nathan; Kathleen E Morton; Mary Ann Toomey; Steven A Rosenberg Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: James N Kochenderfer; Robert P T Somerville; Tangying Lu; James C Yang; Richard M Sherry; Steven A Feldman; Lori McIntyre; Adrian Bot; John Rossi; Norris Lam; Steven A Rosenberg Journal: Mol Ther Date: 2017-07-13 Impact factor: 11.454
Authors: Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall Journal: Nat Rev Clin Oncol Date: 2017-09-19 Impact factor: 66.675
Authors: Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245
Authors: Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz Journal: J Clin Oncol Date: 2010-07-26 Impact factor: 44.544
Authors: Lorraine Springuel; Caroline Lonez; Bertrand Alexandre; Eric Van Cutsem; Jean-Pascal H Machiels; Marc Van Den Eynde; Hans Prenen; Alain Hendlisz; Leila Shaza; Javier Carrasco; Jean-Luc Canon; Mateusz Opyrchal; Kunle Odunsi; Sylvie Rottey; David E Gilham; Anne Flament; Frédéric F Lehmann Journal: BioDrugs Date: 2019-10 Impact factor: 7.744